- Home
- CCCC vs ONCH Comparison
CCCC vs ONCH Comparison
Compare CCCC & ONCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | ONCH |
|---|---|---|
| Founded | 2015 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.4M | 220.8M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CCCC | ONCH |
|---|---|---|
| Price | $2.15 | $10.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 35.3K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $10.16 |
| 52 Week High | $3.84 | $10.63 |
Technical Indicators
Market Signals| Indicator | CCCC | ONCH |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | N/A |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.23 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 32.99 | 0.00 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About ONCH 1RT Acquisition Corp. Class A Ordinary Share
1RT Acquisition Corp is a blank check company.